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Racism and health
Challenge to racism must continue
Editor—As McKenzie highlights in his edi-
torial, the emphasis to date has been on the
role of racism in recruitment and career
development.1 This must continue despite
initiatives and legislation such as the recent
Race Relations Amendment Act, as racism
still exists in the NHS.2 We need to continue
to challenge racism not only from our
colleagues but also from our patients—zero
tolerance is needed.3
The importance of racism on health and
health care will not diminish owing to
increasing migration to the United King-
dom particularly from east European coun-
tries. The often hostile reception of the
public, media, and some politicians rein-
forces the negative attitudes that prevail,4
and these may manifest through acute and
chronic stress to the detriment of the
individual. Research on evaluating the
mechanism for racism and health outcomes
is in early infancy; most studies are being
conducted in the United States. We agree
with McKenzie that further funding is
needed in this area.
The biological models alluded to seem
plausible, but before investigating these
further substantial research needs to be
done first to define, measure, and validate
“racism” as an epidemiological variable.
Then we need studies to disentangle the
effect of racism on health. Urgency and
opportunity exist to initiate a national ethnic
cohort study within the planned UK
Biobank study (www.ukbiobank.ac.uk) to
include examination of the effect of racism
on health outcomes.
Paramjit S Gill clinical senior lecturer
Department of Primary Care and General Practice,
University of Birmingham Medical School,
Birmingham B15 2TT
p.s.gill@bham.ac.uk
Raj S Bhopal Bruce and John Usher professor of
public health
Department of Community Health Sciences,
University of Edinburgh Medical School,
Edinburgh EH8 9AG
Competing interests: None declared.
1 McKenzie K. Racism and health. BMJ 2003;326:65-6.
(11 January.)
2 Race Relations (Amendment) Act 2000. Available at:
www.legislation.hmso.gov.uk/acts/acts2000/
20000034.htm (accessed 17 Jan 2003).
3 Wildt de G, Gill P, Chudley S, Heath I. Racism and general
practice—time to grasp the nettle. Br J Gen Pract (in press).
4 Modood T,Berthoud R,Lakey J,Nazroo J, Smith P,Virdee S,
Beishon S, eds. Ethnic minorities in Britain. Diversity and
disadvantage. London: Policy Studies Institute, 1997.
Author’s reply
Editor—I agree with Gill and Bhopal that
the challenge to racism must continue, and
there should be zero tolerance. Racism is
complex, and so the response will need to be
wide based.
Research has been conducted in the
United States and United Kingdom on the
nature of racism. There will always be a need
to refine measures, but survey tools and
instruments are available, supported by a
robust literature, that are being used in the
United Kingdom.
I support the need for a national ethnic
minority cohort study to try to disentangle
the effects of racism on health. This should be
separate from Biobank. Biobank samples
people aged over 45. It will not be able to
address the effect of racism on younger
people and pregnant women. It will not
address ecological effects. It will not address
the changing demographics of areas or
populations that may influence the impact of
racism on health.
Somemay be uncomfortable with the sci-
entific paradigm of Biobank and may call for
consultation with black and ethnic minority
groups. Oversampling of people of black and
ethnicminority groups within Biobank would
be useful. If the samples simply reflected the
percentage of the ethnic minority popula-
tions over 45 in the United Kingdom the
study may not have sufficient power for
meaningful subgroup analysis. It could be
argued that the research would not have
delivered equity because it is not as useful to
minority groups. It could be argued that it is
therefore discriminatory. I am unsure
whether this could lead to a challenge under
the Race Relations Amendment Act.
However, oversampling in Biobank
should not be confused with a proper
research effort that addresses the issue of rac-
ism and health. Biobank may be useful, but it
is too limited to offer the answers required.
Kwame McKenzie senior lecturer in transcultural
psychiatry
Department of Psychiatry and Behavioural
Sciences, Royal Free and University College
Medical School, London NW3 2PF
k.mckenzie@rfc.ucl.ac.uk
Competing interests: None declared.
Australia’s Aboriginals suffer
disproportionate burden of ill health
Editor—McKenzie has highlighted the
association between racism, morbidity and
mortality.1 I respond as an epidemiologist
for Aboriginal health in central Australia.
About 20 000 Aboriginal people live in
central Australia, most of them in small
communities scattered across the vast desert
area. Aboriginal Australians have a dispro-
portionate burden of ill health compared
with their non-Aboriginal counterparts.
Their life expectancy is about 20 years lower,
and 58% of Aboriginals die before the age of
55.2 Their morbidity load is far greater than
that of non-Aboriginals, and the bulk of
morbidity is due to chronic diseases such as
diabetes, heart disease, and chronic obstruc-
tive airways disease. From birth weight to life
expectancy, disparities in health indicators
between the two populations are glaring.
Much of the research work in the past
has been directed at socioeconomic status,
cultural factors, and position in the social
hierarchy. Not much attention has been
given to racism and its effects on health sta-
tus. McKenzie’s editorial implies that racism
may be aetiologically important in the
development of illness.3 Overt or implicit
racial discrimination is recognised to be the
underlying cause for poor health status.4
Although research based evidence is
scant to show that racism being the under-
lying cause for health inequalities in central
Australia, there are some setbacks in the
system that may be aggravating the disparity:
x Inappropriate responses from health
services
x Lack of coordination among various
categories of healthcare staff
x Absence of mechanisms for evaluating
the effectiveness of services
x Lack of a public health and epidemio-
logical approach
x High turnover of healthcare staff.
These factors may well be the conse-
quences of intrinsic racism in the system.
The disturbing health inequalities between
Aboriginal and non-Aboriginal population
are acknowledged time and again, but no
appropriate action seems to be in place to
address these problems and reduce the
inequity gap. Requisite skills and knowledge
to rectify these problems may be lacking
among key managerial staff. I hope the
above factors are given serious considera-
tion while planning services that would in
turn generate effective solutions.
Ruby Kaul epidemiologist
Department of Health and Community Services,
PO Box 721, Alice Springs, Northern Territory
0871, Australia
Competing interests: None declared.
1 McKenzie K. Racism and health. BMJ 2003;326:65-6.
(11 January.)
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2 Epidemiology Branch. The health and welfare of territorians.
Darwin: Territory Health Services, 2001.
3 Gee GC. A multilevel analysis of the relationship between
institutional and individual racial discrimination and
health status. Am J Public Health 2002;92:615-23.
4 Winnie MS. Statement of World Health Organization.
Durban, September 2001.
Spirituality and clinical care
Placebo or not—we may never know
Editor—I agree with Culliford that knowing
your patients better makes for a better thera-
peutic relationship.1 Often—for example, in
terminal care or when physical measures do
not have an impact on any disease—being
able to relate in “wider” terms can increase
the potential for healing. But I disagree with
Culliford on the question of methodology.
Most religions and other arenas of spir-
ituality use ritualised gestures, incantations,
prayers, symbolism, and rites. Unless you
believe that these processes have effects
through a perceived extracorporeal being,
power, or energy, the effect is presumed to
come from within patients themselves. But
the placebo effect is inherently based on its
own camouflage. Once you know you’re
taking placebo then the magic is lost.
The entire effect is dependent on your
“faith” in the procedure. Although I might
deliberately use the placebo effect in my
pharmacological treatment of patients, is it
not an unethical deceit for me to portray a
facade of spirituality for their benefit when I
don’t believe it myself? If that is true then
what is Culliford suggesting? Might it be that
my deficiencies as a non-believer translate
into deficiencies as a doctor? Perhaps I don’t
really want an answer to that.
Daniel R Nethercott senior house officer, palliative
medicine
Holme Tower, Marie Curie Centre, Penarth,
South Glamorgan CF64 3YR
danielnethercott@hotmail.com
Competing interests: DRN is a practising atheist.
1 Culliford L. Spirituality and clinical care. BMJ
2002;325:1434-5. (21 December.)
Spiritual care based primarily on
happiness is dangerous
Editor—Culliford’s editorial reflects a
resurgent interest in spiritual aspects of
healing through discontent with a purely
materialistic world view.1 Our culture does
not believe in a pure scientific reductionist
model that says we are made solely of a
chemical structure (witness the Princess
Diana experience and films such as Sixth
Sense and Star Wars). Our experience tells us
there is a greater depth to life, and I welcome
Culliford’s recognition of this as central in
healthcare provision. However, a case for
spiritual awareness and treatment based pri-
marily on outcomes of happiness and
wellbeing is dangerous. Leading patients to
believe that spirituality brings happiness
may cause upset through disappointment or
more seriously propound disregard for spir-
itual truth—“It doesn’t matter what you
believe as long as it makes you happy.”Of far
greater importance is “Is it true or not?”
Consider Christianity as an example.
The experience of many is that faith brings a
deep joy that surpasses day to day happiness
and upset. However, Christianity does not
always bring happiness. Christ claimed he
was God’s son and was crucified for it. Many
who followed him since have been martyred
for their beliefs, and countless more suffer
daily persecution for being called “Chris-
tian.” Living out the Christian faith in itself is
hard work. Therefore it matters whether this
faith is based on truth.2
The spiritual side of clinical care is
important.We should be careful, however, to
avoid misleading spiritual platitudes that
bring happiness at the expense of truth.
Matt J Hawker senior house officer, ophthalmology
Worcestershire Acute Hospitals NHS Trust,
Worcester WR5 1DD
mands@freenetname.co.uk
Competing interests: MH is a Christian.
1 Culliford L. Spirituality and clinical care. BMJ
2002;325:1434-5. (21 December.)
2 Holy Bible. 1 Corinthians 15:17-19. (New International
Version.) International Bible Society, 1984.
Spirituality is not everyone’s cup of tea
for treating addiction
Editor—Culliford’s editorial about spiritu-
ality in medicine raises some important
issues.1 In alcohol and drug treatment the
spiritual dimension can play a part in recov-
ery. The 12 step model developed by
Alcoholics Anonymous has several impor-
tant therapeutic elements, one of which is
promoting the development of spirituality,
and the large Project MATCH study of
drinking outcomes found 12 step facilitation
to be as effective as other forms of
psychological treatment.2
We recently conducted a questionnaire
survey of 60 people attending Narcotics
Anonymous groups in theWest Midlands.We
asked the attenders to rate their level of group
attendance and participation, their belief in a
higher power, and the amount of time that
they devoted to any form of spiritual practice.
The results showed that 90% of the partici-
pants had a belief in a power greater than
themselves, and on average 50% allowed time
for spiritual practices at least once daily.
Linear regression analysis showed that spir-
itual practices, along with attendance and
engagement with the self help groups, were
significant predictors of abstinence in this
group of substance misusers.
The finding that participants allow
themselves some time to engage in spiritual
activities every few days is consistent with
the work of Finney and Maloney, who found
meditation to be an effective means of
preventing relapse in this group.3 It also
links to Geisler’s work, which shows that
spiritual practices combined with psychoso-
cial treatment are effective aids to misusers
in reducing their drug use,4 as well as to
other work that indicates that prayer and
meditation positively influences coping.5
We believe, however, that the spiritual
dimension is potentially a double edged
sword for engagement in self-help groups.
Although Alcoholics and Narcotics Anony-
mous have over two million members
worldwide, few of the people whom we treat
use this free and readily available form of
long term help. Our clinical experience
implies that the perceived “religious” or
spiritual element of the process is a strong
reason to stop attending self help groups of
these organisations, particularly in the early
stages.
Ed Day specialist registrar in addiction psychiatry
ejday@blueyonder.co.uk
Simon Wilkes psychologist
Alex Copello consultant psychologist
Addictive Behaviours Centre, Birmingham B4 6SX
Competing interests: None declared.
1 Culliford L. Spirituality and clinical care. BMJ
2002;325:1434-5. (21 December.)
2 Project MATCH Research Group. Matching alcoholism
treatments to client heterogeneity: Project MATCH post
treatment drinking outcomes. J Studies Alcohol 1997;58(1):
7-29.
3 Finney JR, Maloney HN. Empirical studies of Christian
prayer: a review of the literature. J Psychol Theol 1985;
13:104-15.
4 Geisler M. Transcendental meditation as a therapeutic tool
for drug users. J Clin Psychol 1978;7:235-55.
5 Hjelle L. Transcendental meditation and psychological
health. Perception Motor Skills 1974;39:623-8.
National service framework for
diabetes leaves questions open
Editor—The much delayed national service
framework for diabetes has major implica-
tions for primary and secondary care
services in England.1 Many of its proposals
are to be welcomed, but some of them are
vague, with little indication of how they can
be implemented.
The most serious problem is the absence
of identified resources to allow improve-
ments in diabetes care to be implemented
effectively. We are informed that there will
be some funding for retinal cameras, but no
indication is given about how the revenue
consequences of major screening pro-
grammes will be addressed. We are told that
funds for the national service framework will
be provided to primary care trusts in the
baseline allocation for general medical serv-
ices, but there is no guarantee that these will
be ringfenced. In many areas new monies
seem to have already been swallowed up by
historical debts.
Much of the focus of the national service
framework is on primary care, but diabetes
expertise is lacking in many practices.2
Developing the necessary skills in primary
care will need an educational programme,
which will depend on local specialist
diabetes services. The Association of British
Clinical Diabetologists has already shown
deficiencies and lack of resources (especially
in numbers of consultants, specialist nurses,
dietitians, and podiatrists) in many specialist
centres,3 so it is hard to see how the
necessary support can be provided.
Already there are major medical
recruitment problems, with trusts being
unable to attract suitable candidates for
posts such as consultant diabetologists.
Without adequate specialist diabetes serv-
ices there is a real risk of substandard
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diabetes care in many districts. The resource
and staffing consequences of the national
service framework need to be addressed
urgently, otherwise its impact will be
minimal, care overall will not improve, and
the morbidity and mortality in the diabetic
population will not be reduced.
Richard H Greenwood chairman
richard.greenwood@nnuh.nhs.uk
K M Shaw honorary treasurer
P Winocour honorary secretary
Association of British Clinical Diabetologists,
London W1P 4HQ
Competing interests: None declared.
1 Mayor S. Government publishes strategy to improve
diabetes care. BMJ 2003;326:121. (18 January.)
2 Williams DRR, Baxter H, Airey CM, Ali S, Turner B.
Diabetes UK funded surveys of the structural provision of
primary care diabetes services in the UK. Diabet Med
2002;19(suppl 4):21-6.
3 Winocour PH, Ainsworth A, Williams DRR. Association of
British Clinical Diabetologists (ABCD) survey of second-
ary care services for diabetes in the UK, 2000. 1. Methods
and major findings.Diabet Med 2002;19:327-333.
Cardiovascular risk scores and
prescribing in diabetes
Using risk tables to assess cardiovascular
risk in type 2 diabetes has drawbacks
Editor—Hall et al describe the use of
primary prevention risk tables in type 2
diabetes.1 We agree that targeting cardiovas-
cular risk in diabetes is a priority, but their
proposals imply an overreliance on risk
scores as the sole determinant of cardiovas-
cular risk assessment in diabetes. This
approach might lead to withholding treat-
ment in some people whose risk is underes-
timated by risk scores.
Unfortunately, the decision at what level
of cardiovascular risk to start lipid lowering
treatment in diabetes is not straightforward.
The authors’ oversimplistic approach,
although convenient, is unscientific and flies
in the face of epidemiological evidence
which suggests that type 2 diabetes should
be regarded as a disease group for
secondary rather than primary prevention.2
Using the Framingham equation to
evaluate cardiovascular risk in diabetes
entails caveats. These include a low baseline
prevalence of diabetes in the Framingham
cohort and the omission from the equation
of triglyceride concentration, an important
determinant of cardiovascular risk in type 2
diabetes.3 The low prevalence of diabetes in
the cohort leads to wide confidence intervals
in the predicted risk. Thus, in a diabetic man
with average risk factors, the upper 95%
confidence interval crosses the 15%, 10 year
threshold from the age of 40 onwards.3
People with risk scores below a chosen
cut-off point may therefore have a higher
true risk. The proposals by Hall et al would
lead to a rigid prescribing protocol whereby
all patients with scores above a threshold
(for example, 15%) would receive treatment,
whereas those below would not. Further-
more, an overemphasis on the risk score
might be at the expense of ignoring other
key factors not represented by the Framing-
ham risk equation, such as ethnic group,
family history, microalbuminuria, and
triglyceride concentration.
Jamie Smith specialist registrar
jamie.smith@virgin.net
Roger Corrall consultant physician
Department of Diabetes and Endocrinology, Bristol
Royal Infirmary, Bristol BS2 8HW
Competing interests: None declared.
1 Hall LML, Jung RT, Leese GP. Controlled trial of effect of
documented cardiovascular risk scores on prescribing.
BMJ 2003;326:251-2. (1 February.)
2 Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laako M.
Mortality from coronary heart disease in subjects with type
2 diabetes and in nondiabetic subjects with and without
prior myocardial infarction. N Engl J Med 1998;339:
229-34.
3 Yeo WW, Yeo KR. Predicting CHD risk in patients with
diabetes mellitus.Diabet Med 2001;18:341-344.
Authors’ reply
Editor—The purpose of our paper was to
identify whether there was clinical value in
having cardiovascular risk scores.We wanted
to identify whether having an integrated sin-
gle score of macrovascular cardiovascular
risk highlights to clinicians that a clinical
issue needs addressing, which influences
their prescribing habits. Our paper indicates
that this is the case and that in the setting of
a busy clinic having to assess a multitude of
individual risk factors may result in cardio-
vascular risk being overlooked. Having
established that an integrated score is useful
to practising clinicians, the next challenge is
to identify an appropriate risk score to use.
Smith and Corrall correctly indicate that
the New Zealand risk score, and others
based on Framingham, all underestimate
the cardiovascular risk in diabetes, although
data from Tayside indicate that this is
probably not to the extent suggested by
Haffner et al.1 2 Also, the level of risk chosen
to start treatment is an arbitrary cut-off
point which can be adjusted—for example,
to 15% from 20%—if thought desirable. The
real answer is to define the epidemiology of
cardiovascular risk in diabetes more accu-
rately so that more accurate tables can be
developed.
Graham P Leese consultant in diabetes
graham.leese@tuht.scot.nhs.uk
Lesley Hall medical student
Roland Jung consultant
Ninewells Hospital, Dundee DD19SY
Competing interests: None declared.
1 Evans JM, Wang J, Morris AD. Comparison of cardiovas-
cular risk between patients with type 2 diabetes and those
who had had a myocardial infarction: cross sectional and
cohort studies. BMJ 2002;324:939-42.
2 Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laako M.
Mortality from coronary heart disease in subjects with type
2 diabetes and in nondiabetic subjects with and without
prior myocardial infarction.N Engl J Med 1998;339:229-34
Failing to bark and barking
Editor—Le Fanu’s Sherlock Holmes style
case of the missing data and dog that failed
to bark had amusing elements but also mis-
understandings, errors, and accusations of
concealment, implying bad faith.1
x Twenty one countries took part in the
World Health Organization’s monitoring
trends and determinants in cardiovascular
disease (MONICA) project, not 27.
x MONICA had set out to validate and
explain such trends. Our 1999 paper on
trend results was big news internationally,
including the BMJ,2 but apparently Le Fanu
missed it.
x Mortality data are freely downloadable
from the World Health Organization. The
dearth of publications on mortality trends in
scientific journals is not from conspiracy.
Any novice can have a go, so editors and
reviewers are overburdened with enthusiasts
trying to prove things badly. Works of schol-
arship may have an uphill fight for
publication because routine mortality statis-
tics are considered trivial and unscientific
compared with laboratory studies.
x Americans did not study immigrants just
from Japan. Studies go back 55 years, classi-
cally contrasting New York’s Italians with its
Jews, and Irish and Norwegians in the
United States with brothers in the home
country, more recently focusing on Hispan-
ics and newer ethnic groups. Disease rates
are easier to study with first generation
migrants, place of birth providing a census
denominator, than later on.
x Smoking shows all or none differences in
one population, where diet has historically
been more uniform. Diet differs greatly
between populations, thereby determining a
population’s susceptibility to cardiovascular
disease and also to specific cancers. The chol-
esterol story is well established, but diet is now
known to contain more varied contributors
to coronary risk than dairy fats alone.
x Le Fanu’s unoriginal suggestion that cor-
onary disease has an infective origin would
not in itself explain why it took 10 years to
cross the Atlantic as an epidemic, and half a
century to reach eastern Europe. Lifestyle
fits better. Existing explanations for disease
trends must give way to better ones, but they
must be more specific than that.
Le Fanu claimed in the Sunday Telegraph
Magazine in 2000 that I published research
that I knew to be false, that was nonsense
and quackery, and that I was a danger to the
public.3 Although now apparently running
with the fox as well as hunting with the
hounds, by characterising MONICA col-
laborators as not barking he claims the
opposite role for himself.
Hugh Tunstall-Pedoe professor of cardiovascular
epidemiology
Cardiovascular Epidemiology Unit, University of
Dundee, Ninewells Hospital, Dundee DD1 9SY
h.tunstallpedoe@dundee.ac.uk
Competing interests: HT-P was a project author
and principal investigator in the WHO
MONICA project.
A longer version of this letter complete with ref-
erences is available at bmj.com/cgi/eletters/
325/7378/1490[30160
1 Le Fanu J. The case of the missing data. BMJ 2002;
325:1490-3. (21 December.)
2 Kmietowicz Z. Heart disease mortality declining with fewer
and less deadly attacks. BMJ 1999;318:1307.
3 Le Fanu J. Scientists who should carry a health warning.
Sunday Telegraph Magazine 2000 (July 9).
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Competing interests
Consent was not obtained
Editor—So, the editor of the BMJ is happy
to coauthor research involving undeclared
deception of subjects and publish it in his
journal.1 Three hundred readers were
unwitting dupes. They took part without
being informed what the real object of the
exercise was, no informed consent here, at
least not by the standard of being willing to
show the subject the research protocol.
This sort of research violates Kant’s
categorical imperative—act as if this were a
universal principle. It seeks payment in a coin
that it debases for others.2 BMJ readers should
be warned: next time a researcher contacts
you for an opinion, it is probably a hoax.
What is ironic about the paper is that the
results have meaning only if the respondents
were more honest than the authors. My
warning to researchers is as follows: if you
deceive your subjects what right have you to
expect they will not do the same to you?3
Stephen J Senn professor of pharmaceutical and heath
statistics
University College London, London WC1E 6BT
stephens@public-health.ucl.ac.uk
Competing interests: SJS is a consultant to the
pharmaceutical industry and an academic. His
career is therefore furthered by publication.
1 Chaudhry S, Schroter S, Smith R,Morris J. Does declaration
of competing interests affect readers’ perceptions? A
randomised trial. BMJ 2002;325:1391-2. (14 December.)
2 Senn SJ. The ignoble lie. J Clin Epidemiol 1992;45:1338-9.
3 Senn SJ. Are placebo run-ins justified? BMJ 1997;314:1191.
Problem is greater than editorial indicates
Editor—The BMJ should be congratulated
for its efforts to avoid bias in the reporting of
scientific work.1 Asking editors and authors
explicitly to state competing interests
reduces the likelihood of bias. As Smith
rightly says, however, we still have some way
to go to the fully transparent world. Much of
the discussion of conflict of interest may
leave the impression that the problem lies in
commercial sponsorship, in particular from
the pharmaceutical and tobacco industries.
The problem may be more widespread,
however. Could researchers in a public
health institute be influenced by political
pressures when the institute is financed
directly by the health ministry? Will the
pressure become stronger when the
research institute is placed within the minis-
try? Can researchers who receive honoraria
for advising government and courts on
tobacco issues be influenced by the fees they
receive? If researchers can be influenced by
commercial sponsorship, and the evidence
here is convincing, why should researchers
be immune to influence from other spon-
sors? Nevertheless, it is not unusual that
research financed by government and other
non-commercial sources is presented with-
out warning the reader that there is a poten-
tial conflict of interest.
My point is not that bias from commer-
cial sponsorship should be belittled but
rather to emphasise that the problem is
greater than Smith’s editorial may indicate.
Policies to avoid bias in the conduct and
reporting of research should be guided by
scientific principles, not by moralism or
prejudice.
Ivar S Kristiansen senior researcher
Institute of Public Health, University of Southern
Denmark, DK-5000 Odense, Denmark
ivarsk@c2i.net
Competing interests: ISK has received salary and
honoraria from several public institutions and
honoraria from several pharmaceutical firms. He
has not received honoraria from the tobacco
industry.
1 Smith R. Making progress with competing interests. BMJ
2002;325:1375-6. (14 December.)
It’s my journal, and I’ll write if I want to
Editor—
Richard and colleagues just walked
Through the door
Like a king with his court.
He says he’s had a great idea
And surely to publish they ought.
Sorry, my muse left on holiday after that.
Please feel free to add some more verses.
Like other respondents, I applaud the BMJ ’s
crusade to enlighten readers about the
issues of conflicting interests.1 The paper by
Chaudhry et al should surely have been sub-
mitted to another journal, or if not then
someone else should have it.2 The BMJ ’s
peer journals are not the BMJ itself.
Could we be informed as to how long
the paper was out at the reviewers and how
quickly it got accepted in its final version? It
was published within six weeks of accept-
ance. That’s nice. I have had work published
in the BMJ, on one occasion after the manu-
script (and I am quoting directly from the
correspondence at the time) “lay in the top
drawer” of a staff statistician’s desk for six
months. I doubt that would ever happen to
an editor’s paper.
These are small points but if the BMJ ’s
crusade is to be credible and successful,
inhouse guidelines about staff submissions
should be torn up and replaced by a rule
that BMJ related work is only submitted
elsewhere.
Jonathan O’B Hourihane senior lecturer, infection,
inflammation, and repair
Mailpoint 218, Southampton University Hospitals
NHS Trust, Southampton SO16 6YD
j.hourihane@soton.ac.uk
Competing interests: None declared.
1 Smith R. Making progress with competing interests. BMJ
2002;325:1375-6. (14 December.)
2 Chaudhry S, Schroter S, Smith R,Morris J. Does declaration
of competing interests affect readers’ perceptions? A
randomised trial. BMJ 2002;325:1391-2. (14 December.)
Authors’ reply
Editor—Medical researchers like Senn are
often very concerned about minor decep-
tion, but its use is common in the social sci-
ences.We at the BMJ have debated the use of
deception with our ethics committee, and it
sees no problem so long as the deception is
minor, the study would be hard or
impossible to do in any other way, and
participants are informed afterwards.
We agree with Kristiansen that all forms
of financial—and non-financial—conflict of
interest are important. Our anxiety is not
only about commercial sponsorship, and we
have had examples in Britain of the govern-
ment trying to interfere with the publication
of research. We disagree, however, with the
implication in Kristiansen’s letter that the
use of scientific principles can avoid the
influence of conflicts of interest. The
evidence suggests otherwise.
There are strong arguments against edi-
tors publishing original research in their
own journals and egregious examples—
from Cyril Burt and Hans Eysenck—of
editors publishing highly dubious research
in their own journals. Nevertheless, it makes
sense for editors to try to publish in their
own journals when the research is con-
ducted on readers, authors, or reviewers
associated with the journals and the results
influence the policies of the journals.
That was the case with this research, and
we do have a declared method of reviewing
research submitted to the BMJ by the edito-
rial staff that excludes editors employed by
the journal at every stage. And we have had
several papers rejected.
Richard Smith editor
Sara Schroter research fellow
BMJ, London WC1H 9JR
Barriers to managing heart
failure in primary care
Heart failure clinics provide crucial link
between primary and secondary care
Editor—Fuat et al surveyed attitudes
towards managing heart failure in general
practice.1 Points of particular note included
difficulties in assessing subtle early signs of
heart failure, difficulties in interpreting
echocardiography reports, and concerns
about the number of drugs recommended
for patients with heart failure.
This study further strengthens the case
for specialist heart failure clinics as outlined
in the national service framework for coron-
ary heart disease.2 Such clinics have a multi-
disciplinary team consisting of physicians
(specialist and primary care), specialist
nurses, and cardiac technicians, and these
teams facilitate a coordinated approach to
diagnosing, assessing, and managing heart
failure. Objective evidence of cardiac dys-
function may be obtained and interpreted
by a cardiologist, with the subsequent
formulation of a treatment strategy.
We believe that this is preferable to
open access echocardiography services,
with the difficulties in interpretation high-
lighted by Fuat et al.1 Specialist dedicated
nursing provides a crucial bridge between
hospital and community care, allowing con-
tinued clinical assessment and appropriate
titration of drug treatment, as well as
continued patient education. Such nursing
has been associated with a significant
reduction in hospital readmission for heart
failure.3 Widespread awareness of current
treatment guidelines seems to be lacking in
primary care; dedicated nursing services
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can be instrumental in implementing
guidelines.
Heart failure is thought to invariably
affect elderly people. This is simply not true.
Clearly the disease becomes more prevalent
with age, but diagnosis is delayed in many
young patients with dilated cardiomyopathy
because of this perception.
Heart failure has a high prevalence and is
associated with a terrible prognosis, despite
the availability of evidence based treatments.
General practitioners are at the sharp end of
an escalating problem, and specialist clinics
provide invaluable support for the growing
burden of chronic heart failure.
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Previous study revealed other factors to
be important in management
Editor—Fuat et al describe an important
problem in their article on diagnosing and
managing heart failure in primary care.1 We
investigated this same issue by semistruc-
tured interviews with individual general
practitioners. This investigation undertaken
in 1998 identified many themes that were
common to Fuat et al’s study using focus
groups of general practitioners.2 However,
two important themes we identified are
absent in this later study.
The first is that discussion of patients
with “suspected heart failure” was very diffi-
cult, general practitioners more readily
identifying with symptom based scenarios,
such as managing breathless patients.
The second theme was “therapeutic
trials.” Most general practitioners described
difficulties in distinguishing between
chronic obstructive pulmonary disease and
heart failure. Several general practitioners
described using bronchodilators or diuretics
to determine which could alleviate symp-
toms, arriving at a symptomatic rather than
pathophysiological diagnosis.
The general practitioners we inter-
viewed were aware of the benefits of
angiotensin converting enzyme inhibitors,
but symptom control seemed to be the focus
of management in many cases. These
additional factors, which featured highly in
the thinking of some practitioners, should
be taken account of in the design of any
future interventions to improve the manage-
ment of heart failure in primary care.
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Congestion charging
Walking classes also need road space
reallocation
Editor—We welcome Roberts’s editorial,
making the health case for the London
congestion charge,1 particularly as the rev-
enue is required to be spent on transport. We
agree that physically active transport such as
walking and cycling is likely to increase. This
must be monitored adequately, with attention
given to changes in activity levels2 and broken
down by sociodemographic groups, to assess
the impacts on health and inequalities.
Other potential effects of congestion
charging include improvement in access for
emergency vehicles. However, not all are
positive: the impact of the policy will depend
on which complementary measures are
introduced at the same time.
Firstly, we disagree that less car travel will
result in fewer crashes; this impact is difficult
to predict.3 It depends whether journey
times are shorter because of less time queu-
ing at junctions or because of higher speeds.
If traffic reduction is greater than was
predicted, travel speeds may become sub-
stantially faster. While shorter journey times
could reduce exposure to the risk of
collisions, higher speeds could increase the
risk by a greater amount.4
Secondly, congestion charging alone
could adversely affect equity: road space
vacated by people who are deterred by the
charge could be occupied by the wealthy,
who are less price sensitive.4
Both effects can be effectively combated
by simultaneously introducing measures to
reallocate road space and giving priority to
buses, preferential access to disabled drivers,
and effective protection to cyclists and pedes-
trians.4 This is largely true of the London
congestion charge, but it is important to con-
sider when other towns and cities follow suit.
Even London has been timid about
pedestrianising road space—Soho and Cov-
ent Garden seem ideal candidates. Experi-
ence shows that whereas such schemes tend
to be initially opposed by local businesses,
once the schemes are implemented they
benefit economically.
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Political polemics are masquerading as
science
Editor—Roberts in his editorial on conges-
tion charging is wrong in almost all of his
assertions.1 The number of cars on the road
in central London has remained stable over
the past 30 years until it fell by 18% last year
(Transport for London statistics). Slow jour-
ney times and congestion are due to more
people working in central London and poor
road management.
Roberts acknowledges that the vulner-
able groups are pedestrians (10-18 times the
accident rate of car drivers per 2 km
journey) and cyclists (13 times the accident
rate per 2 km journey), yet he thinks that
increasing the size of both of these
vulnerable groups by encouraging people to
walk or cycle will decrease the number of
accidents. Statistical nonsense.
It is generally agreed that the only
pollutant to constitute a health hazard at
current levels is a small particle emission.
How can moving from clean petrol driven
cars to dirty diesel buses (buses do not have
to conform to any emission standards) help
this?
Since there are only about 16 state
schools within the congestion charge zone it
is absurd to suggest it is going to make
mothers happy to allow their children to
walk to school throughout the country.
To compare Ken Livingstone to Edwin
Chadwick is particularly absurd. Chadwick’s
plans for sanitation were drawn up at the
request of parliament and largely imple-
mented without opposition. He is remem-
bered for his controversial Poor Law Act of
1834, which confined the poor to institu-
tions where families were separated and
deliberately subjected to discomfort “to
punish them for their indolence.” There may
be a case for congestion charges but it is not
on the grounds of improving health or
safety. I cannot believe that this editorial was
critically reviewed before publication.
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